Skip to Main Content

Regeneron Pharmaceuticals (REGN) is about to have a chance to prove that its pricey, seldom-used cardiovascular drug can actually improve patients’ lives — an outcome that would also allow it to remove the air quotes from its “blockbuster” product.

Some time this quarter, Regeneron will release clinical trial data showing whether Praluent, an injected therapy that blasts away bad cholesterol, is better than yesteryear drugs at preventing heart attack, stroke, and hospitalization. That will determine whether the company can compete with Amgen (AMGN), its bitter rival in marketplace and courtroom alike.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!